Loading company analysis...
Eli Lilly is delivering exceptional growth through Mounjaro and Zepbound while expanding its cardiometabolic pipeline and manufacturing capacity.
Keep researching
This is a data-generated overview, not a published Rithvik Chethan research rating. Figures use the latest usable company filing and may differ from vendor-calculated trailing metrics.
The rating combines business quality, fundamentals, growth, valuation, technicals, and risk. It is a research opinion, not a price target or prediction.
Eli Lilly develops and sells medicines across cardiometabolic health, oncology, immunology, and neuroscience. Its most important current products are Mounjaro for diabetes and Zepbound for obesity, both based on tirzepatide.
The business model depends on patent-protected medicines, clinical development, regulatory approvals, manufacturing scale, physician adoption, insurance coverage, and global commercialization. Lilly's current advantage is a leading incretin portfolio, strong clinical data, a broad pipeline, and expanding production capacity.
Second-quarter revenue increased 48% to $22.97 billion. U.S. revenue grew 33%, while revenue outside the U.S. increased 80%.
Mounjaro revenue rose 91% to $9.94 billion and Zepbound revenue rose 46% to $4.93 billion. Together, the two products represented nearly 65% of quarterly revenue, showing both extraordinary demand and meaningful product concentration.
Gross margin improved to 85.8%. Net income increased 25% to $7.10 billion, and diluted EPS reached $7.94. Earnings included $2.78 billion of acquired in-process research and development charges and $703 million of impairment, restructuring, and other special charges.
The business produces substantial cash, but capacity expansion and acquisitions have increased leverage and capital needs.
Near $1,186 per share, Lilly's equity value was roughly $1.1 trillion. The stock traded near 11.5 times the latest quarterly revenue run rate and roughly 37 times annualized first-half diluted EPS.
That valuation is supported by exceptional growth and high margins, but it assumes continued market leadership, successful launches, and a long runway for obesity and diabetes treatment.
Lilly's live panel recalculates trend, EMA ribbon, 200-day EMA, RSI, MACD, volume, ATR, support, and resistance after each completed daily candle. Pharmaceutical stocks can gap on clinical and regulatory news, so risk should be defined before catalysts.
The automated panel estimates fair value gaps, order blocks, structure changes, and nearby liquidity. Large earnings or trial gaps can remain important reference zones. Confirm any setup with price action and volume rather than treating a detected zone as proof of institutional buying.
The most important checkpoints are prescription growth, realized pricing, capacity, Foundayo uptake, clinical data, safety, regulatory approvals, and the updated full-year outlook.
Final view: Lilly earns a bullish 84 because it combines extraordinary revenue growth, high margins, strong cash flow, market-leading medicines, and a deep pipeline. The premium valuation, product concentration, rising debt, manufacturing demands, and clinical risk keep the score from moving higher.
This website and its analysis are provided for educational and informational purposes only. Nothing on this site constitutes financial, investment, legal, or tax advice, or an offer to buy or sell any security. Market data is provided by Finnhub and other third-party sources and may be delayed, incomplete, or inaccurate. The author may hold positions in securities discussed, and opinions may change without notice. Past performance does not guarantee future results. Always conduct your own research and consult a qualified financial professional before making investment decisions.
Johnson & Johnson combines a diversified medicine pipeline and global MedTech portfolio with dependable cash flow, while patent erosion and litigation remain important risks.
AbbVie has successfully shifted growth toward Skyrizi, Rinvoq, and neuroscience, while acquisitions, high debt, and product concentration remain central risks.
UnitedHealth is showing a meaningful earnings and medical-cost recovery across UnitedHealthcare and Optum, but membership contraction, regulation, and investigations remain central risks.
Automatically refreshed from Finnhub. Open each source to evaluate how the development affects the thesis.
Eli Lilly (NYSE:LLY) delivered a quarter that forced Wall Street to catch up to its own numbers. On August 5, the company reported second-quarter revenue of $23.0 billion, up 48% from a year earlier, and used the momentum to raise its full-year sales and profit targets. Shares moved higher the same day as investors focused […]
Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 47.7% year on year to $22.97 billion. The company’s full-year revenue guidance of $86 billion at the midpoint came in 0.6% above analysts’ estimates. Its non-GAAP profit of $8.38 per share was 27.3% above analysts’ consensus estimates.
Eli Lilly (NYSE: LLY) reported that its KRAS G12C inhibitor olomorasib received FDA Breakthrough Therapy designation for advanced pancreatic cancer in patients with a KRAS G12C mutation. The company entered a new clinical trial collaboration with Amplia Therapeutics to test olomorasib in combination with Amplia's FAK inhibitor narmafotinib in advanced non small cell lung cancer. These developments highlight Eli Lilly's efforts to broaden its oncology portfolio beyond its diabetes and obesity...
Recalculated automatically from daily market data. Values are cached for one hour and use the latest completed candle. Smart money zones are algorithmic estimates and should be confirmed on the chart.
It's not much of a rivalry yet.
